We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Ultra-Portable POC Molecular Diagnostics System to Instantly Detect Infectious Diseases

By LabMedica International staff writers
Posted on 02 Feb 2024

Infectious diseases pose a significant threat to human health and have a substantial economic impact globally. More...

Timely and accurate identification of pathogens is key for prompt treatment, improved patient outcomes, and halting the spread of diseases. Traditional pathogen detection methods are usually conducted in well-equipped clinical labs, relying on advanced equipment and specialized staff. Furthermore, pre-analytical steps such as lengthy transportation can skew results and extend turnaround times (TAT), hindering effective control of infectious diseases, especially in areas with limited resources. Now, a rapid RT-PCR platform being developed to provide highly accurate, rapid, and affordable diagnoses of infectious diseases at point-of-care and near-patient settings could enable immediate treatment initiation and curtail potential disease transmission.

Novel Microdevices (Baltimore, MD, US) is advancing its affordable, portable, rapid, multiplex, and user-friendly PCR testing solution for infectious diseases. This innovative technology simplifies complex scientific processes, typically carried out in high-complexity labs, into a compact device. Point-of-care diagnostics offered by the Novel Dx device allow for immediate results, enabling prompt action instead of the extended waiting times associated with traditional laboratory tests. The Novel Dx device employs Nucleic Acid Amplification Techniques (NAAT), which is the same method used in clinical reference laboratories, to detect the genetic material of pathogens.

The Novel Dx molecular testing platform utilizes polymerase chain reaction (PCR) technology in a disposable cartridge. The patient's sample is added to this cartridge, which is then inserted into the Novel Dx system. The system analyzes genetic sequences to identify diseases and detect genetic mutations that may make bacteria resistant to antibiotics. Novel Dx is capable of providing lab-quality results in less than 15 minutes, allowing patients to be tested, diagnosed, and treated all within a single visit, thus eliminating the wait for results from more complex labs. Designed for portability and weighing just four pounds, the Novel Dx diagnostic tool is battery-operated, making it especially suitable for use in low-resource settings and low-and middle-income countries (LMICs).


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.